REMD 477

Drug Profile

REMD 477

Alternative Names: AMG477; REMD477

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer REMD Biotherapeutics
  • Class Antibodies; Antihyperglycaemics
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Preclinical Metabolic disorders

Most Recent Events

  • 17 Aug 2017 Phase-II clinical trials in Type-1 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT03117998)
  • 13 Jun 2017 Efficacy data from a phase I trial in Type 1 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 20 Apr 2017 REMD Biotherapeutics plans a phase II trial for Type-1 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT03117998)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top